Email
Print
In Vitro Diagnostics Quality Controls Market - Forecast(2024 - 2030)
In Vitro Diagnostics Quality Controls Market Overview
The In Vitro Diagnostics Quality Controls Market size is estimated to
reach $1,432 million by 2026, growing at a CAGR of 5.6% during the forecast period
2021-2026. In-vitro diagnostic tests are conducted on collected blood tissue
samples in order to detect various communicable and non-communicable diseases.
Moreover, they can also be used to monitor a patient’s health, cure diseases, and
also enable medical professionals to identify the most effective treatment
procedure or therapy for the patient. IVQ Quality Controls are products used to
evaluate the quality and accuracy of these tests. Key technologies used for IVD
quality controls include molecular diagnostics, blood-based controls,
immunochemistry, and clinical chemistry. The rapid growth of the global
geriatric population is anticipated to drive the market for IVD testing and
quality control products. However, the lack of stringent regulations regarding
quality controls in low and middle-income countries acts as a major challenge
for the In Vitro Diagnostics (IVD) Quality Controls Industry.
Report Coverage
The report: “In Vitro Diagnostics Quality Controls Market Forecast (2021-2026)”, by Industry ARC, covers an in-depth
analysis of the following segments of the In Vitro Diagnostics Quality Controls Market.
By Product and Service Type: Quality Control
Products, Data Management Solutions, and Quality Assurance Services.
By Technology: Immunochemistry, Clinical
Chemistry, Molecular Diagnostics, Microbiology, Hematology, Coagulation &
Hemostasis, and Others.
By Manufacturer: Third-Party Controls and Original
Equipment Manufacturer Controls.
By End User: Hospitals, Clinical
Laboratories, Academic and Research Institutes, and Others.
By
Geography: North America (U.S., Canada, and
Mexico), Europe (Germany, UK, France, Italy, Spain, Russia, and Rest of
Europe), Asia-Pacific (China, India, Japan, South Korea, Australia & New
Zealand, and Rest of Asia-Pacific), South America (Brazil, Argentina, and Rest
of South America) and Rest of World (the Middle East and Africa).
Key Takeaways
- Geographically, the North American In Vitro Diagnostics Quality Controls Market accounted for the largest share in 2020 owing to the presence of well-developed healthcare infrastructure and increasing lifestyle diseases in the region.
- The growing number of certified clinical laboratories providing IVD diagnostics is driving the market during the forecast period. However, the high cost of IVD quality control products is predicted to hamper growth, especially in developing regions.
- Detailed analysis on the Strength, Weaknesses, and
Opportunities of the prominent players operating in the market will be provided
in the In Vitro Diagnostics
(IVD) Quality Controls Report.
For More Details on This Report - Request for Sample
In Vitro Diagnostics Quality Controls Market Segment Analysis - By Technology
Based on Technology,
the In Vitro Diagnostics Quality Controls Market is segmented into Immunochemistry, Clinical Chemistry,
Molecular Diagnostics, Microbiology, Hematology, Coagulation & Hemostasis,
and other technologies. The Immunochemistry segment is anticipated to
have the largest share of the market in 2020 and is poised to dominate
the market during the forecast period 2021-2026 owing to the surge in cases of
cancer. Immunochemistry involves the use of antibodies to identify certain antigen
markers in tissue or blood sample. It helps predict the prognosis of tumors,
diagnose tumors with unknown origin and also predict the patient response
towards therapeutic procedures. The molecular diagnostics segment is projected
to grow the fastest at a CAGR of 6.3% owing to the global rise in the Covid-19
Pandemic and the resulting demand for Polymerase Chain Reaction (PCR) tests for
diagnosis.
In Vitro Diagnostics Quality Controls Market Segment Analysis - By End User
The In-Vitro
Diagnostics (IVD) Quality Controls Market based on End User can be further
segmented into Hospitals, Clinical
Laboratories, Academic and Research Institutes, and Others. The Hospitals
segment accounted for the largest share of the market in 2020. The
growth of the segment can be attributed to the rise in the number of admissions
and consultation visits, the presence of more experienced healthcare professionals, and higher convenience for the patient. Hospitals provide services such as
consulting, diagnostic testing, treatment, surgery, and therapy in a single
location. The clinical laboratories segment is also anticipated to witness
significant growth during the forecast period at a CAGR of 6.4% owing to the absence
of a separate department for diagnosis in many hospitals in low and middle-income
countries. Therefore, patients in the region may have to undergo IVD in these
centers before the results can be shared with the medical professionals in the
hospital.
In Vitro Diagnostics Quality Controls Market Segment Analysis - By Geography
The In-Vitro Diagnostics (IVD) Quality Controls Market based on Geography can be segmented into North America, Europe, Asia-Pacific, South America, and the Rest of the World. The North American segment is projected to dominate the In Vitro Diagnostics Quality Controls Market during the forecast period 2021-2026 with a market share of 36% owing to the presence of highly developed healthcare infrastructure, growing geriatric population, rising cases of cancer, and high patient awareness regarding the importance of early diagnosis and treatment. Moreover, the growth in the private and public expenditure on R&D is leading to the introduction of more innovative technologies in the region, thereby promoting growth. The Asia Pacific region is predicted to register the fastest growth owing to the increase in communicable and non-communicable diseases and growth in public healthcare funding in major emerging economies like China and India.
In Vitro Diagnostics Quality Controls Market Drivers
Increase in Geriatric Population is Projected to Drive Market Growth
The rise in Covid-19 infections is Anticipated to Boost Product Demand
The covid-19 pandemic has resulted in at least
219 million infections and more than 4.55 million deaths worldwide. The
emergence of new variants such as the delta variant has posed a significant
challenge for vaccinations and treatment. This is boosting the demand for IVD
diagnostics such as PCR for accurately determining if an individual is
infected. This is driving the market for IVD diagnostics quality control as high
accuracy is demanded from the testing kits. False positives or false negatives
may result in the patient not getting adequate treatment or cause them to
unknowingly spread the virus to other individuals.
In Vitro Diagnostics Quality Controls Market Challenges
The High Cost of IVD Quality Control Equipment is Anticipated to Hamper Market Growth
Absence of Stringent Regulations in Developing Regions is Projected to Limit Growth Opportunities
The absence of stringent regulations
regarding diagnostic device quality and accuracy significantly decreases the
demand for the IVD quality controls market in developing regions. Setting up a quality
control system is expensive and the laboratory is also required to have
dedicated personnel for the system. However, since the regulations are not
stringent, most of the laboratories choose to avoid them altogether to save
costs. For instance, in India, the National Accreditation Board for Testing and
Calibration Laboratories (NABL) provides accreditation to testing and
calibration of clinical laboratories in the country. However, only around 202
labs across the country were NABL accredited for Covid-19 testing, of which
only 15 were government laboratories.
In Vitro Diagnostics Quality Controls Market Industry Outlook:
Product launches, mergers and acquisitions, joint
ventures, and geographical expansions are key strategies adopted by players in
the In Vitro Diagnostics Quality Controls Market. The top 10 companies of
the industry include:
- Abbott Laboratories
- Bio-Rad Laboratories Inc
- F. Hoffmann-La Roche AG
- Quidel Corporation
- bioMerieux Inc
- Qnostics Ltd
- Microbiologics Inc
- SeraCare Life Sciences Inc
- Thermo Fisher Scientific
- ZeptoMetrix Corporation.
Partnerships/Product Launches:
- In June 2021, Abbott announced that it has received CE Mark for its Panbio COVID-19 Antigen Self-Test. The test kit will be for sale directly to consumers for use in the detection of the SARS-CoV-2 virus in adults and children with or without symptoms. This is aimed to improve rapid testing for the virus in school, office, and home environments.
- In October 2019, Thermo Fisher Scientific announced the launch of the Thermo Scientific Acrometrix BCR-ABL molecular quality control panel. This panel is intended for use as an external control panel for analytical validation of BCR-ABL test methods. The Acrometrix BCR-ABL Panel is the first full-process molecular control for challenging validated BCR-ABL assay performance.